drugset / Trial / NCT02411591
A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
SequentialOpen-labelTreatment
Summary
This is medical research evaluating the safety and efficacy of two new medicines (necitumumab and abemaciclib), administered in combination in participants affected by a defined type of advanced lung cancer (stage IV non-small-cell lung cancer).
Timeline
- Start
- 2015-06-04
- Primary completion
- 2017-06-23
- Completion
- 2019-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 100 mg | Oral |
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Abemaciclib | Small molecule | 200 mg | Oral |
| Subject | Necitumumab | Monoclonal antibody | 800 mg | Intravenous |